论文部分内容阅读
目的探讨抗病毒药物联合应用对乙肝标志物的作用。方法将45例乙肝“大三阳”、HBV DNA阳性患者随机分为3组,A组15例应用阿德福韦酯联合干扰素;B组15例单用干扰素;C组不用抗病毒药物仅用一般护肝治疗作用对照,疗程均为180 d。结果HBeAg阴转率A组达73.30%、B组46.70%、C组为0%;HBV DNA阴转率(<103Cop ies/m l)A组达73.30%、B组53.30%、C组为0%。结论乙肝病毒体内复制指标不用抗病毒药物短期内无变化;单用干扰素抗病毒治疗仅半数标志物变化;而应用干扰素联合阿德福韦酯抗病毒治疗可使乙肝标志物近2/3发生变化,短期内复制指标受到明显抑制,未发现明显毒副作用。表明以上二药联合抗病毒不仅能提高疗效而且能缩短疗程,不失为抗病毒较为理想的疗法。
Objective To investigate the effect of combination of antiviral drugs on hepatitis B markers. Methods Forty-five patients with hepatitis B virus infection and HBV DNA positive were randomly divided into three groups: 15 cases in group A received adefovir dipivoxil combined with interferon; 15 cases in group B received interferon alone; Viral drugs only general liver protection treatment control, treatment were 180 d. Results The negative rate of HBeAg was 73.30% in group A, 46.70% in group B and 0% in group C. The DNA negative rate (<103 copies / ml) in group A was 73.30%, in group B was 53.30%, in group C was 0% . Conclusion HBV replication in vivo indicators do not have no short-term changes in antiviral drugs; interferon antiviral therapy with only half of the changes in markers; and interferon plus adefovir dipivoxil treatment can make hepatitis B markers nearly 2/3 Changes in the short-term replication index was significantly inhibited, no significant side effects were found. These two drugs combined antiviral therapy not only can improve the efficacy but also shorten the course of treatment, after all, antiviral therapy is more ideal.